2023
DOI: 10.1007/s13311-022-01338-0
|View full text |Cite
|
Sign up to set email alerts
|

A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (“line 61”) Mice

Abstract: Development of neuroprotective therapeutics for Parkinson’s disease (PD) is facing a lack of translation from pre-clinical to clinical trials. One strategy for improvement is to increase predictive validity of pre-clinical studies by using extensively characterized animal models with a comprehensive set of validated pharmacodynamic readouts. Mice over-expressing full-length, human, wild-type alpha-synuclein under the Thy-1 promoter (Thy1-aSyn line 61) reproduce key features of sporadic PD, such as progressive … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
15
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 15 publications
(15 citation statements)
references
References 173 publications
0
15
0
Order By: Relevance
“…In Thy1-aSyn mice, α-synuclein aggregation and microgliosis coincide with progressive development of motor and nonmotor symptoms, supporting its frequent choice for preclinical studies. 20 Thy1-aSyn mice develop manifest parkinsonism with loss of striatal dopamine and L-dopa-responsive deficits at 14 months of age. 23 At 1 to 6 months of age used in this study, Thy1-aSyn mice represent a model of premanifest PD.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…In Thy1-aSyn mice, α-synuclein aggregation and microgliosis coincide with progressive development of motor and nonmotor symptoms, supporting its frequent choice for preclinical studies. 20 Thy1-aSyn mice develop manifest parkinsonism with loss of striatal dopamine and L-dopa-responsive deficits at 14 months of age. 23 At 1 to 6 months of age used in this study, Thy1-aSyn mice represent a model of premanifest PD.…”
Section: Discussionmentioning
confidence: 99%
“…Thy1-aSyn (line 61) transgenic mice overexpressing human WT α-synuclein under the Thy-1 promoter were maintained on a mixed C57BL/6-DBA/2 background as described previously. 18,20 Polymerase chain reaction amplification analysis was performed on ear tissue samples collected both at birth and at the completion of the experiment. Only mice with confirmed genotypes were included in the analyses.…”
Section: Venglustat In Thy1-asyn Micementioning
confidence: 99%
See 1 more Smart Citation
“…Since the discovery of the role of alpha-synuclein in these disorders through human genetics and pathology, animal models based on the expression of the protein have supplanted previous toxinbased models which only reproduced the end point of the pathological process, the death of dopaminergic neurons, rather than the pathological process. Extensive animal studies are beginning to clarify the contribution of various forms of alpha-synuclein to the pathology (Peelaerts and Baekelandt [5]), to elucidate the mechanisms of disease spread first suspected on the basis of human postmortem pathological studies (Pinto-Costa et al [6]), and to model previously neglected non-motor aspects of Parkinson's disease (as reviewed by Richter et al [7]). Furthermore, Stefanova [8] shows how genetic manipulations in mice led to the generation of a model of Multiple Systems Atrophy, a rare disease in which alphasynuclein surprisingly accumulates in glial cells rather than in neurons.…”
mentioning
confidence: 99%
“…Furthermore, Stefanova [8] shows how genetic manipulations in mice led to the generation of a model of Multiple Systems Atrophy, a rare disease in which alphasynuclein surprisingly accumulates in glial cells rather than in neurons. Each of these models contributes to a better understanding of synucleopathies, and some provide meaningful tools for the preclinical testing of novel therapies [7,8]. In the absence of a neuroprotective treatment that has been validated in the clinic, their predictability remains uncertain.…”
mentioning
confidence: 99%